Treatment of persistent and recurrent acromegaly

Journal of Clinical Neuroscience

Volumn 18, Issue 2, 2011, Pages 181-190

  Del Porto, Lana A ^a   Liubinas, Simon V ^a   Kaye, Andrew H ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acromegaly; Persistent; Radiosurgery; Radiotherapy; Recurrent; Somatostatin analogues; Transsphenoidal

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT;

ACROMEGALY; ARTHROPATHY; COMMON BILE DUCT STONE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GALLSTONE; GASTROINTESTINAL PAIN; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSURGERY; RADIOTHERAPY; RECURRENT DISEASE; REVIEW; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; COMBINED MODALITY THERAPY; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; RECURRENCE;

EID: 78651424914     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2010.10.003     Document Type: Review

References (97)

1. P. Nomikos, M. Buchfelder, and R. Fahlbusch The outcome of surgery in 668 patients with acromegaly using the current criteria of biochemical cure Eur J Endocrinol 152 2005 379 387
2. G. Baumann Acromegaly Endocrinol Metab Clin 16 1987 685 703
3. L. Alexander, D. Appleton, and R. Hall Epidemiology of acromegaly in the Newcastle region Clin Endocrinol 12 1980 71 79
4. L. Katznelson An update on treatment strategies for acromegaly Expert Opin Pharmacother 9 2008 2273 2280
5. I. Holdaway, and R. Rajasoorya Epidemiology of acromegaly Pituitary 2 1999 29 41
6. R. Grunstein, K. Ho, and C. Sullivan Effect of octreotide, a somatostatin analogue, on sleep apnoea in patients with acromegaly Ann Intern Med 121 1994 478 483
7. Y. Matano, T. Okada, and A. Suzuki Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels Am J Gastroenterol 100 2005 1154 1160
8. S. Orme, R. McNally, and R. Cartwright Mortality and cancer incidence in acromegaly: a retrospective cohort study J Clin Endocrinol Metab 83 1998 2730 2734
9. H. Vasen, K. Van Erpecum, and F. Roelfsema Increased prevalence of colonic adenomas in patients with acromegaly Eur J Endocrinol 131 1994 234 237
10. D. Clemmons Role of insulin-like growth factor-1 in the diagnosis and management of acromegaly Endocr Pract 10 2004 362 371
11. C. Roberts, S. Lasky, and W. Lowe Molecular coding of rat insulin-like growth factor I complimentary deoxyribonucleic acids: differential messenger ribonucleic acid processing of regulation by growth hormone in extrahepatic tissue Mol Endocrinol 1 1987 243 248
12. W. Daughaday, and P. Rotwein Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations Endocr Rev 10 1989 68 91
13. J. Herrington, and C. Carter-Su Signaling pathways activated by the growth hormone receptor Trends Endocrinol Metab 12 2001 252 257
14. R.G. Rosenfeld Molecular mechanisms of IGF-I deficiency Horm Res 65 2006 15 20
15. L. Sze, C. Schmid, and K. Bloch Effect of transsphenoidal surgery on sleep apnoea in acromegaly Eur J Endocrinol 156 2007 321 329
16. I. Holdaway, R. Rajasorrya, and G. Gamble Factors influencing mortality in acromegaly J Clin Endocrinol Metab 89 2004 667 674
17. B. Swearingen, F. Barker, and L. Katznelson Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly J Clin Endocrinol Metab 83 1998 3419 3426
18. E. Laws, D. Piepgras, and R. Randall Neurosurgical management of acromegaly. Results related to patients treated between 1972 and 1977 J Neurosurg 50 1979 454 461
19. D. Ross, and C. Wilson Results of transsphenoidal microsurgery for growth hormone secreting pituitary adenomas in a series of 214 patients J Neurosurg 68 1988 854 867
20. R. Fahlbusch, J. Honneger, and M. Buchfelder Surgical management of acromegaly Endocrinol Metab Clin North Am 21 1992 669 691
21. A. Bates, W. Van't Hoff, and J. Jones An audit of outcome of treatment in acromegaly Q J Med 86 1993 293 299
22. D. Clemmons, J. Van Wyk, and E. Ridgeway Evaluation of acromegaly by radioimmunoassay of somatomedin-C N Engl J Med 301 1979 1138 1142
23. E. Dimaraki, C. Jaffe, and R. DeMott-Friberg Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up J Clin Endocrinol Metab 87 2002 3537 3542
24. G. Oppizzi, M. Petroncini, and D. Dallabonzana Relationship between somatomedin-C and growth hormone levels in acromegaly: basal dynamic evaluation J Clin Endocrinol Metab 63 1986 1348 1353
25. S. Peacy, and S. Shalet Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly Ann Clin Biochem 38 2001 297 303
26. P. Freda, A. Nuruzzaman, and C. Reyes Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-1 levels J Clin Endocrinol Metab 89 2004 495 500
27. A. Guistina, A. Barkan, and F. Casanueva Criteria for cure in acromegaly: a consensus statement J Clin Endocrinol Metab 85 2000 526 529
28. E.M. Lim, and P. Pullen Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus Conference of the Growth Hormone Research Society and the Pituitary Society Clin Biochem Rev 26 2005 41 43
29. M. Buchfelder, S. Brockmeier, and R. Fahlbusch Recurrence following transsphenoidal surgery for acromegaly Horm Res 35 1991 113 118
30. R. Clayton, P. Stewart, and S. Shalet Pituitary surgery for acromegaly. Should be done by specialists Br Med J 319 1999 588 589
31. O. Serri, M. Somma, and R. Comtois Acromegaly: biochemical assessment of cure after long-term follow-up of transsphenoidal selective adenomectomy J Clin Endocrinol Metab 61 1985 1185 1189
32. S. Melmed, F. Casanueva, and F. Caravagnini Guidelines for acromegaly management J Clin Endocrinol Metab 87 2002 4054 4058
33. Australian Pituitary Foundation Website: < http://www.pituitary.asn. au/ThePituitaryGland/ConditionsIntroduction/Acromegaly.aspx >. Kellyville, NSW, Australia, 2006.
34. P. Rao-Balakrishna, C. Lees, and M. Roberts Value of early postoperative growth hormone assessment in acromegaly surgery Endocr Abstr 13 2007 217
35. G. Besser, P. Burman, and A. Daly Predictors and rates of treatment-resistant tumour growth in acromegaly Eur J Endocrinol 153 2005 187 193
36. M. Krieger, W. Couldwell, and M. Weiss Assessment of long term remission of acromegaly following surgery J Neurosurg 98 2003 719 724
37. Cooperman M, Diabetes Insipidus, emedicine, 2009, < http://emedicine.medscape.com/article/117648-overview >. Medscape 2010, Omaha, NE, USA.
38. Swearingen B. Frequently asked questions about transsphenoidal surgery for pituitary adenomas: a patient guide. The Neuroendocrine Clinical Center and Pituitary Tumour Center, Massachusetts General Hospital and Harvard Medical School, 2002; 8. < http://pituitary.mgh.harvard.edu/TranssphenoidalSurgery. htm >.
39. C. Lissett, S. Peacy, and I. Laing The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas Clin Endocrinol 49 1998 653 657
40. S. Yamada, T. Aiba, and K. Takada Retrospective analysis of long-term surgical results in acromegaly Clin Endocrinol 45 1996 291 298
41. S. Ahmed, M. Elsheikh, and I. Stratton Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience Clin Endocrinol 50 1999 561 567
42. H. Long, H. Beauregard, and M. Somma Surgical outcome after repeated transsphenoidal surgery in acromegaly J Neurosurg 85 1996 239 247
43. S. Yamada, N. Fukuhara, and K. Oyama Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly Neurosurgery 67 2010 949 956
44. S. Melmed, K. Ho, and A. Klibanski Clinical review 75: Recent advances in pathogenesis, diagnosis and management of acromegaly J Clin Endocrinol Metab 80 1995 3395 3402
45. J. Wass Long-term effects of radiotherapy for acromegaly Metabolism 45 1996 107 108
46. N. Biermasz, H. Van Dulken, and F. Roeslfsema Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels Clin Endocrinol 53 2000 321 327
47. J. Powell, S. Wardlaw, and K. Post Outcome of radiotherapy for acromegaly using normalisation of insulin-like growth factor 1 to define cure J Clin Endocrinol Metab 85 2000 2068 2071
48. N. Biermasz, H. Van Dulken, and F. Roelfsema Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly J Clin Endocrinol Metab 85 2009 2476 2482
49. A. Barkan, I. Halasz, and K. Dornfeld Pituitary irradiation is ineffective in normalising plasma insulin-like growth factor 1 in patients with acromegaly J Clin Endocrinol Metab 82 1997 3187 3191
50. G. Barrande, M. Pittino-Lungo, and J. Coste Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients with acromegaly J Clin Endocrinol Metab 82 2000 3779 3785
51. R. Attanasio, P. Epaminonda, and E. Motti Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study J Clin Endocrinol Metab 88 2003 3105 3112
52. R. Tsang, J. Brierley, and T. Panzanella Role of radiation therapy in clinical hormonally active pituitary adenomas Radiother Oncol 41 1996 45 53
53. W. McCollough, R. Marcus, and A. Rhoton Long term follow-up of radiotherapy for pituitary adenoma: the absence of late recurrence after ≥4500 Gy Int J Radiat Oncol Biol Phys 21 1991 607 614
54. M. Brada, B. Rajan, and D. Traish The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas Clin Endocrinol (Oxf) 38 1993 571 578
55. M. McCord, J. Buatti, and E. Fennell Radiotherapy for pituitary adenoma: long-term outcome and sequelae Int J Radiat Oncol Biol Phys 39 1997 437 444
56. H. Danesh-Meyer Radiation-induced optic neuropathy J Clin Neurosci 15 2007 95 100
57. E. Laws, J.P. Sheehan, and J.M. Sheehan Stereotactic radiosurgery for pituitary adenomas: a review of the literature J Neurooncol 69 2004 257 272
58. M. Mitsumori, D.C. Chrieve, and E. Alexander III Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas Int J Radiat Oncol Biol Phys 42 1998 573 580
59. T.C. Witt, D. Kondziolka, and J.C. Flickinger Gamma knife radiosurgery for pituitary tumors Prog Neurol Surg 14 1998 114 127
60. H.K. Inoue, H. Kohga, and M. Hirato Pituitary adenomas treated by microsurgery with or without gamma knife surgery: experience in 122 cases Stereotact Funct Neurosurg 72 1999 125 131
61. M. Mokry, S. Ramschak-Schwarzer, and J. Simbrunner A six year experience with the postoperative radiosurgical management of pituitary adenomas Stereotact Funct Neurosurg 72 1999 88 100
62. G.C. Feigl, C.M. Bonelli, and A. Berghold Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function J Neurosurg 97 2002 415 421
63. B.E. Pollock, and P.C. Carpenter Stereotactic radiosurgery as an alternative to fractionated radiotherapy for patients with recurrent or residual nonfunctioning pituitary adenomas Neurosurgery 53 2003 1086 1094
64. Carroll P, Jenkins P, Acromegaly. Chapter 5a Endotext (www.endotext.org ). < http://www.endotext.org/neuroendo/neuroendo5e/neuroendo5e.html > 2007.
65. F. Castinetti, and T. Brue Radiotherapy and radiosurgery of pituitary adenomas Presse Med 38 2009 133 139
66. C.C. Pan, and J.A. Hayman Recent advances in radiation oncology J Neuroophthalmol 24 2004 251 258
67. S. Roug, A. Rasmussen, and M. Juhler Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit Eur J Endocrinol 162 2010 685 694
68. S. Imran, I. Fleetwood, and C. O'Connell Outcome of stereotactic radiotherapy for patients with uncontrolled acromegaly Can J Neurol Sci 36 2009 468 474
69. L. Ma, A. Sahgal, and M. Descovich Equivalence in dose fall-off for isocentric and nonisocentric intracranial treatment modalities and its impact on dose fraction schemes Int J Radiat Oncol 76 2010 943 948
70. J. Jagannathan, J. Sheehan, and N. Pouratian Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery Neurosurgery 62 2008 1262 1269
71. J. Jezkova, J. Marek, and V. Hana Gamma knife radiosurgery for acromegaly - long-term experience Clin Endocrinol (Oxf) 64 2006 588 595
72. F. Castinetti, D. Taleb, and J. Kuhn Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion J Clin Endocrinol Metab 90 2005 4483 4488
73. Y. Iwai, K. Yamanaka, and M. Yoshimura Gamma knife radiosurgery for growth-hormone-producing adenomas J Clin Neurosci 17 2007 299 304
74. P. Freda, L. Katznelson, and A. van der Lely Long acting somatostatin analogue therapy of acromegaly: a meta-analysis J Clin Endocrinol Metab 90 2005 4465 4473
75. A. Danoff, and D. Kleinberg Somatostatin analogs as primary medical therapy for acromegaly Endocrine 20 2003 291 297
76. S. Lamberts, A. van der Lely, and W.W. de Herder Somatostatin analogues: future directions Metabolism 45 1996 104 106
77. A. Ben-Shlomo, and S. Melmed Pasireotide - a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease IDrugs 10 2007 885 895
78. A. Farrall, J. Glusman, and M. Ruffin Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from phase II extension study Endocr Abstr 16 2008 OC1.4
79. J. Wass, M. Thorner, and D. Morris Long-term treatment of acromegaly with bromocriptine Br Med J 1 1977 875
80. A. Colao, D. Ferone, and P. Marzullo Effect of different dopaminergic agents in the treatment of acromegaly J Clin Endocrinol Metab 82 1997 518 523
81. S. Melmed, I. Jackson, and D. Kleinberg Current treatment in acromegaly J Clin Endocrinol Metab 83 1998 2646 2652
82. F. Maneschi Reappraisal of bromocriptine treatment for acromegaly Horm Res 12 1980 191
83. R. Abs, J. Verhelst, and D. Maiter Cabergoline in the treatment of acromegaly: a study in 64 patients J Clin Endocrinol Metab 83 1998 374 378
84. P. Maruzullo, D. Ferone, and C. Di Somma Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients Pituitary 1 1999 115 120
85. W. Drake Experience with pegvisomant in the treatment of acromegaly Growth Horm IGF Res Supplement A 2001 S111 S114
86. S. Lamberts The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of analogs in the treatment of human pituitary tumors Endocr Rev 9 1988 417 436
87. V. Herman-Bonert, K. Zib, and J. Scarlett Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs J Clin Endocrinol Metab 85 2000 2958 2961
88. A. Van der Lely, W. de Herder, and S. Lamberts New medical treatment for acromegaly Pituitary 2 1999 89 92
89. P. Trainer, W. Drake, and L. Katznelson Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant N Engl J Med 342 2000 1171 1177 (Pubitemid 30211048)
90. C. Higham, T. Chung, and J. Lawrence Long-term experience of pegvisomant therapy as a treatment for acromegaly Clin Endocrinol 71 2009 86 91
91. Van de Lely A, Lamberts S, Barkan A et al. A six week double blind, placebo controlled study of growth hormone antagonist, B 2036-PEG (Trovert) in acromegalic patients. Abstracts from the 80th Annual Meeting of the Endocrine Society, 24-27 June 1998, New Orleans, Louisiana.
92. P. Trainer ACROSTUDY: the first five years Eur J Endocrinol 161 2009 S19 S24
93. P. Trainer, S. Ezzat, and G. D'Souza A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly Clin Endocrinol 71 2009 549 557
94. S. Neggers, W. de Herder, and J. Janssen Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients Eur J Endocrinol 160 2009 529 533
95. I. Schreiber, M. Buchfelder, and M. Droste Treatment of acromegaly with the GH receptor pegvisomant in clinical practice, safety and efficacy evaluation from the German pegvisomant observational study Eur J Endocrinol 156 2007 75 82
96. Scottish Medicines Consortium, Assessment of Pegvisomant, NHS, Glasgow, Scotland (www.scottishmedicines.org.uk ) http://www.scottishmedicines.org.uk/ files/pegvisomant-Somavert-Resubmission-May-06-FINAL-for-website.pdf 2006.
97. Connock M, Adi Y, Bayliss S et al. The clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review. Database of Abstracts of reviews of effects, 2008, Accession number 12008104822.